{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T07:38:15Z","timestamp":1782891495671,"version":"3.54.5"},"reference-count":13,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2018,3,14]]},"abstract":"<jats:p>A novel administration strategy of immunoglobulin treatment is represented by injection of recombinant human hyaluronidase (rHUPH20) with subcutaneous immunoglobulins. The use of facilitated subcutaneous immunoglobulin treatment (fSCIG) for the treatment of autoimmune conditions is yet to be investigated. We present the case of a 56-year-old female patient with pemphigus vulgaris predominantly of the oral mucous membranes, previously treated for 24 months with azathioprine and medium doses of steroids, with only partial remission. When she came to our attention, a concomitant newly diagnosed infiltrating ductal breast cancer limited the use of immunosuppressive agents. She was started with fSCIG (25\u2009g\/monthly). After 18 months of follow-up, her breast cancer has been successfully treated and a substantial decrease of the rate of bullous mucous lesions and improvement of time to lesion healing and resolution was observed. fSCIG might represent a steroid-sparing tool for the treatment of selected cases of pemphigus vulgaris.<\/jats:p>","DOI":"10.1136\/bcr-2017-223302","type":"journal-article","created":{"date-parts":[[2018,5,30]],"date-time":"2018-05-30T11:35:50Z","timestamp":1527680150000},"page":"bcr-2017-223302","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Facilitated subcutaneous immunoglobulin treatment in pemphigus vulgaris"],"prefix":"10.1136","volume":"2018","author":[{"given":"Massimo","family":"Radin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Roccatello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Baldovino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savino","family":"Sciascia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,5,30]]},"reference":[{"key":"2025042703444382000_2018.may29_1.bcr-2017-223302.1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/RHU.0000000000000201","article-title":"Use of intravenous immunoglobulin in patients with active vasculitis associated with concomitant infection","volume":"21","author":"Simoes","year":"2015","journal-title":"J Clin Rheumatol"},{"key":"2025042703444382000_2018.may29_1.bcr-2017-223302.2","first-page":"41","article-title":"Treatment with intravenous immunoglobulins in systemic lupus erythematosus: a series of 52 patients from a single centre","volume":"32","author":"Camara","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"2025042703444382000_2018.may29_1.bcr-2017-223302.3","doi-asserted-by":"publisher","DOI":"10.1185\/03007990903432900"},{"key":"2025042703444382000_2018.may29_1.bcr-2017-223302.4","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.4.4.427"},{"key":"2025042703444382000_2018.may29_1.bcr-2017-223302.5","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1208\/s12248-015-9782-0","article-title":"Clinical immunogenicity of rHuPH20, a hyaluronidase enabling subcutaneous drug administration","volume":"17","author":"Rosengren","year":"2015","journal-title":"Aaps J"},{"key":"2025042703444382000_2018.may29_1.bcr-2017-223302.6","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/41.4.367"},{"key":"2025042703444382000_2018.may29_1.bcr-2017-223302.7","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.3390\/ijms18122532","article-title":"Paraneoplastic pemphigus: insight into the autoimmune pathogenesis, clinical features and therapy","volume":"18","author":"Paolino","year":"2017","journal-title":"Int J Mol Sci"},{"key":"2025042703444382000_2018.may29_1.bcr-2017-223302.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2011.03.009"},{"key":"2025042703444382000_2018.may29_1.bcr-2017-223302.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.01.012"},{"key":"2025042703444382000_2018.may29_1.bcr-2017-223302.10","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/cei.12519","article-title":"Subcutaneous immunoglobulin: facilitated infusion and advances in administration","volume":"178 Suppl 1","author":"Wasserman","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"2025042703444382000_2018.may29_1.bcr-2017-223302.11","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s10875-016-0298-x","article-title":"Long-term tolerability, safety, and efficacy of recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulin for primary immunodeficiency","volume":"36","author":"Wasserman","year":"2016","journal-title":"J Clin Immunol"},{"key":"2025042703444382000_2018.may29_1.bcr-2017-223302.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2004.06.053"},{"key":"2025042703444382000_2018.may29_1.bcr-2017-223302.13","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s40257-014-0101-9","article-title":"Treatment of pemphigus vulgaris and pemphigus foliaceus: a systematic review and meta-analysis","volume":"15","author":"Atzmony","year":"2014","journal-title":"Am J Clin Dermatol"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2017-223302","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T10:44:47Z","timestamp":1745750687000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2017-223302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,30]]},"references-count":13,"alternative-id":["10.1136\/bcr-2017-223302"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2017-223302","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,30]]}}}